Please assess the completion status of the following clinical trial:

Trial Title: Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Daily intake of low-dose Aspirin (ASA) - The subject must fulfill at least one of the following (a-e):~* Aged ≥65 years.~* Aged ≥18 years and with a documented history of uncomplicated peptic ulcer(s).~* Aged ≥60 years and naïve to low-dose ASA (ie, treatment started within 1 month prior to randomization).~* Aged ≥60 years and with stable coronary artery disease.~* Aged ≥60 years and with complaints of upper gastrointestinal (GI) symptoms that, as judged by the investigator, requires an Esophagogastroduodenoscopy (EGD) and with the finding of ≥5 gastric and/or duodenal erosions at the baseline endoscopy.~Exclusion Criteria:~* Peptic ulcer(s) at baseline esophagogastroduodenoscopy (EGD).~* Reflux esophagitis Los Angeles (LA) classification grade C or D at baseline~* History of peptic ulcer complications such as clinically significant bleeding and/or perforation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esomeprazole 40 mg (Type: EXPERIMENTAL): Esomeprazole 40 mg
- Esomeprazole 20 mg (Type: EXPERIMENTAL): Esomeprazole 20 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).